References
- Schultheiss TE, Kun LE, Ang KK, Stephens LC. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 1995; 31: 1093–112
- St Clair WH, Arnold SM, Sloan AE, Regine WF. Spinal cord and peripheral nerve injury: current management and investigations. Semin Radiat Oncol 2003; 13: 322–32
- Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 2003; 42: 620–33
- Grosu AL, Andratschke N, Nieder C, Molls M. Retreatment of the spinal cord with palliative radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52: 1288–92
- Andratschke NH, Nieder C, Price RE, Rivera B, Tucker SL, Ang KK. Modulation of rodent spinal cord radiation tolerance by administration of platelet-derived growth factor. Int J Radiat Oncol Biol Phys 2004; 60: 1257–63
- Yoo KM, Yoo BG, Kim KS, Lee SU, Han BH. Cerebral lipiodol embolism during transcatheter arterial chemoembolization. Neurology 2004; 63: 181–3
- Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682–91
- van den Bent MJ, Hilkens PH, Sillevis Smitt PA, van Raaij-van den Aarssen VJ, Bontenbal M, Verweij J. Lhermitte's sign following chemotherapy with docetaxel. Neurology 1998; 50: 563–4
- Hsu Y, Sood AK, Sorosky JI. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol 2004; 27: 14–8
- Wist EA, Sommer HH, Ostenstad B, Risberg T, Fjaestad K. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 2004; 43: 11–4